BioFocus and InterMed Discovery Announce Marketing Collaboration

21-Jul-2011 - BioFocus and InterMed Discovery GmbH (IMD) announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed. Under the terms of the collaboration, IMD will make its natural ...

Cognis develops two more active ingredients for weight management and cognitive performance from InterMed Discovery

15-Jul-2010 - Cognis and InterMed Discovery (IMD) are continuing their strategic cooperation: Cognis has now exclusively licensed two new active ingredients for weight management and cognitive performance from IMD, further expanding the company’s innovation pipeline. Tests on the products Cognis has already ...

InterMed Discovery Receives Michael J. Fox Foundation Award for IMD-026259

21-Jan-2010 - InterMed Discovery (IMD) announced that it has received an award from The Michael J. Fox Foundation for Parkinson’s Research for its programme to develop IMD-026259 as a pharmaceutical treatment to challenge neuro-degeneration in Parkinson’s disease (PD). PD is a disease of progressive ...

InterMed Discovery Acquires Sustainable Source for Omega-3 Fatty Acid

20-Aug-2009 - InterMed Discovery (IMD) announced the acquisition of unique microbial Omega-3 fatty acid production strains and related know-how from the University of Saarland. This innovative microbial source has the potential to produce Omega-3 more sustainably and reliably compared to established ...

InterMed Discovery Announces Collaboration Agreement With the Lead Discovery Center

06-Apr-2009 - InterMed Discovery (IMD announced the start of a screening project for the Lead Discovery Center GmbH (LDC), a Max-Planck-Innovation company. The LDC was founded in 2008 in close proximity to IMD at the University Campus at Dortmund and forms an essential part of Max-Planck-Innovation's Drug ...

Cognis licenses further active ingredients for weight management and heart health from InterMed Discovery

23-Mar-2009 - Cognis and InterMed Discovery (IMD) announced that Cognis has exclusively licensed two further product candidates from IMD: one is a new functional ingredient, which shows promise in the area of weight management and the other provides beneficial effects for heart health. Using its unique ...

InterMed Discovery and Axxam Announce Joint Research Agreement for the Identification of Novel Natural Functional Ingredients

10-Mar-2009 - InterMed Discovery (IMD) and Axxam SpA announced that their joint research efforts have proved to be successful in providing a technology platform that offers, in addition to screening solutions, the discovery of natural bioactive compounds. These bioactive compounds are particularly valuable to ...

InterMed Discovery and Biotropics Malaysia Berhad enter long-term Strategic Collaboration Agreement

11-Sep-2008 - InterMed Discovery and Biotropics Malaysia Berhad announced a long-term Strategic Collaboration Agreement under which Biotropics will work with InterMed Discovery to investigate and commercialise products derived from Malaysia’s rich biodiversity and multicultural traditions. The two companies ...

InterMed Discovery achieves Proof-of-Principle for IMD-026260

Small molecule anti-cancer drug candidate based on Hif-1 modulation

07-Aug-2008 - InterMed Discovery GmbH announced that it has established proof-of-principle in a pre-clinical study for its optimized lead compound IMD-026260, an anti-cancer drug candidate. IMD-026260 is a fully synthetic small molecule derived from a natural product lead compound. The optimized lead displays ...